BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16579858)

  • 1. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
    Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
    BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.
    Webster JD; Yuzbasiyan-Gurkan V; Kaneene JB; Miller R; Resau JH; Kiupel M
    Neoplasia; 2006 Feb; 8(2):104-11. PubMed ID: 16611403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.
    Downing S; Chien MB; Kass PH; Moore PE; London CA
    Am J Vet Res; 2002 Dec; 63(12):1718-23. PubMed ID: 12492288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
    Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
    Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.
    Ma Y; Longley BJ; Wang X; Blount JL; Langley K; Caughey GH
    J Invest Dermatol; 1999 Feb; 112(2):165-70. PubMed ID: 9989791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
    Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
    Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours.
    Schlieben P; Meyer A; Weise C; Bondzio A; Gruber AD; Klopfleisch R
    J Comp Pathol; 2013 May; 148(4):318-22. PubMed ID: 22935087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
    Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
    Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis.
    Jones CL; Grahn RA; Chien MB; Lyons LA; London CA
    J Vet Diagn Invest; 2004 Mar; 16(2):95-100. PubMed ID: 15053358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
    Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J
    Vet J; 2019 May; 247():71-74. PubMed ID: 30971355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.
    London CA; Galli SJ; Yuuki T; Hu ZQ; Helfand SC; Geissler EN
    Exp Hematol; 1999 Apr; 27(4):689-97. PubMed ID: 10210327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation and methylation status of KIT and TP
    Vozdova M; Kubickova S; Fictum P; Cernohorska H; Fröhlich J; Rubes J
    Vet Comp Oncol; 2020 Sep; 18(3):438-444. PubMed ID: 31574575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.
    Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H
    Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats.
    Dank G; Chien MB; London CA
    Am J Vet Res; 2002 Aug; 63(8):1129-33. PubMed ID: 12171166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in Exons 8 and 11 of
    Chen P; Marconato L; Sabattini S; Kiupel M
    Vet Sci; 2022 Sep; 9(9):. PubMed ID: 36136708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors.
    Thompson JJ; Morrison JA; Pearl DL; Boston SE; Wood GA; Foster RA; Coomber BL
    Vet Pathol; 2016 May; 53(3):545-58. PubMed ID: 26459517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
    Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
    BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline.
    Marconato L; Zorzan E; Giantin M; Di Palma S; Cancedda S; Dacasto M
    J Vet Intern Med; 2014; 28(2):547-53. PubMed ID: 24372836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
    Meyer A; Gruber AD; Klopfleisch R
    J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.